The inhibition of glutaminase by CB-839 not only limits tumor cell growth but also can be combined with anti-PD-1 immunotherapy to promote the glucose metabolism, epigenetic reprogramming, and cytotoxicity functions within T cells, improving the antitumor effects of immune cells [116]. The gene discussed is PDCD1; the disease is neoplasm.